GET DAILY SIGNALSHyperfine (HYPR) Achieves Record Q3 2026 Revenue with +73% Year-over-Year Growth
Key Takeaways
- Hyperfine reported record third quarter 2026 revenue of $6.0 million, up 73% year over year and 53% sequentially.
- Net loss narrowed to $0.06 per share, beating the consensus estimate of a $0.08 loss.
- Gross margin reached a record 56.7%, marking the company's fifth consecutive quarter above 50%.
- The company sold 14 Swoop portable MRI (magnetic resonance imaging) systems, up 75% from 8 units a year earlier.
- Net cash burn fell 29% sequentially to $5.6 million, and for the first time quarterly revenue exceeded net cash burn.
- Full-year 2026 revenue guidance was reaffirmed at $20 million to $22 million.
- For more on Hyperfine's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper, data-driven coverage.
- Discover timely trade ideas and market opportunities by exploring Trending AI Robots.
Putting the Quarter in Context
Hyperfine, the health technology company behind the first FDA-cleared AI-powered portable brain MRI system, remains in a high-growth phase ahead of profitability. This quarter’s results provide a useful test of whether the company can expand revenue while narrowing losses and extending its cash runway. Following 45% year-over-year revenue growth in the second quarter, the focus was on whether commercial traction in U.S. hospitals, neurology offices, and international markets would hold. Beyond the top line, progress on gross margin and cash burn offers insight into how efficiently the “land-and-expand” model is developing.
Breaking Down the Reported Numbers
Hyperfine posted its strongest quarterly results to date for the period ended September 30, 2026. Revenue reached a record $6.0 million, rising 73% from $3.4 million in the third quarter of 2025 and 53% from the second quarter of 2026. The company sold 14 systems, a 75% increase from 8 units in the prior-year period, with gains across U.S. hospital, U.S. office, and international channels. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Gross profit hit a record $3.4 million, up 83% year over year, and gross margin expanded to a record 56.7% from 53.8% a year earlier. Operating loss narrowed to $7.3 million, the narrowest quarterly operating loss and a 19% improvement year over year. Net loss came in at $6.0 million, or $0.06 per share, versus $11.0 million, or $0.14 per share, in the same period last year. The per-share result beat the consensus estimate of a $0.08 loss by $0.02. Net cash burn declined 29% sequentially to $5.6 million, and quarterly revenue exceeded net cash burn for the first time. Management reaffirmed full-year 2026 revenue guidance of $20 million to $22 million.
How the Market Responded
Hyperfine shares rose in after-hours trading after the report, reflecting the earnings-per-share beat and the first quarter in which revenue topped net cash burn. The results supported a story of improving operating leverage, with revenue up 53% sequentially while operating expenses increased less than 2%. That said, sentiment entering the print had been cautious: the stock had fallen roughly 21% over the prior three months and more than 30% over the prior year, highlighting ongoing investor questions about profitability and future financing needs.
What to Watch Going Forward
Looking ahead, the key question is whether Hyperfine can maintain its revenue momentum while keeping the expense discipline that supported this quarter’s margin gains. The reaffirmed full-year 2026 revenue guidance of $20 million to $22 million points to continued growth in the fourth quarter, backed by new and follow-on health system orders and the international rollout of the next-generation Model 2 scanner.
Regulatory and clinical milestones remain important potential catalysts. Hyperfine completed enrollment in its Contrast PMR study and expects to submit a 510(k) application to the FDA by the end of 2026, which could expand the clinical uses of the Swoop system. Recent CE and UKCA marking approvals also support expansion in Europe and the U.K.
Investors will track unit sales and average selling prices, gross margin sustainability, the pace of cash burn, and the company’s cash runway. Given that Hyperfine has indicated it will need additional financing in the future, attention will also stay on the balance sheet and any capital-raising moves. Execution on both commercial scale and expense control will ultimately shape whether current momentum leads to a clearer path to profitability.
Exploring AI Tools for Stock Analysis
One tool I’ve found helpful for this kind of research is Tickeron’s AI Screener. It lets me filter stocks and ETFs by technical patterns, fundamentals, trends, and AI signals, which helps surface relevant names more quickly than manual searches. I’ve used it to compare Hyperfine with other healthcare technology companies and to identify similar high-growth profiles.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HYPR sees its Stochastic Oscillator climbs out of oversold territory
On November 04, 2026, the Stochastic Oscillator for HYPR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 59 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +8.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPR advanced for three days, in 181 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HYPR as a result. In 93 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for HYPR turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
HYPR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HYPR crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
HYPR broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HYPR entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.076) is normal, around the industry mean (4.142). P/E Ratio (-1.945) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.340) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. HYPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement